Recommended medications are under-prescribed in elderly patients with atrial fibrillation (AF), coronary artery disease (CAD), and congestive heart failure (CHF). The relationship between under-prescribing and comorbidity is unclear.
Design:
Single-day observational study.
Methods:
Analysis of medications taken by patients aged 80 years or over at the time of their admission to cardiology units of 32 French hospitals. Comorbidity was measured using the Charlson comorbidity index (CCI).
Results:
The study included 510 patients (57% men, mean age 85 years). History of AF, CHF, and CAD was present in 213 (42%), 199 (39%), and 187 (37%) patients, respectively. CCI was 0 in 110 (22%), 1–2 in 215 (42%), and ≥3 in 185 (36%) patients. Vitamin K antagonists (VKA) were prescribed to 105 (49%) and aspirin to 86 (40%) patients with AF. CCI did not influence VKA prescription but influenced aspirin use, with lower prescription rates in patients with CCI 1–2 than CCI 0 or CCI ≥3 (p = 0.02). In CHF, angiotensin-converting enzyme inhibitors (ACEI) and β-blockers were prescribed to 80 (40%) and 96 (48%) patients, respectively. Rates of prescription of ACEI, β-blockers, statins, and aspirin in patients with CAD were 43%, 56%, 56%, and 66%, respectively. CCI level did not influence any medication use in CHF and CAD.
Conclusion:
Even in the absence of comorbidity, elderly patients with major cardiovascular diseases are denied from indicated medical treatments probably because of their age alone. Implementing measures to enhance awareness of treatment benefits and promote appropriate prescribing is necessary.
FeinbergWMBlackshearJLLaupacisA. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med1995; 155(5): 469–473.
2.
KattainenASalomaaVHarkanenT. Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s. Eur Heart J2006; 27(3): 296–301.
3.
RogerVLWestonSARedfieldMM. Trends in heart failure incidence and survival in a community-based population. JAMA2004; 292(3): 344–350.
4.
WilmothJR. Demography of longevity: past, present, and future trends. Exp Gerontol2000; 35(9–10): 1111–1129.
5.
HuovinenEHarkanenTMartelinT. Predicting coronary heart disease mortality – assessing uncertainties in population forecasts and death probabilities by using Bayesian inference. Int J Epidemiol2006; 35(5): 1246–1252.
6.
CherubiniAOristrellJPlaX. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med2011; 171(6): 550–556.
7.
LeePYAlexanderKPHammillBG. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA2001; 286(6): 708–713.
8.
AlexanderKPRoeMTChenAY. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol2005; 46(8): 1479–1487.
9.
KomajdaMHanonOHochadelM. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J2009; 30(4): 478–486.
10.
MantJHobbsFDFletcherK. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet2007; 370(9586): 493–503.
11.
van WalravenCHartRGConnollyS. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke2009; 40(4): 1410–1416.
12.
FribergLHammarNRinghM. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J2006; 27(16): 1954–1964.
13.
McCormickDGurwitzJHGoldbergRJ. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med2001; 161(20): 2458–2463.
14.
KomajdaMHanonOHochadelM. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J2007; 28(11): 1310–1318.
15.
HavranekEPAbramsFStevensE. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med1998; 158(18): 2024–2028.
16.
KrumholzHMRadfordMJWangY. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA1998; 280(7): 623–629.
17.
McLaughlinTJSoumeraiSBWillisonDJ. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med1996; 156(7): 799–805.
18.
HanlonJTSchmaderKERubyCM. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc2001; 49(2): 200–209.
19.
ShrankWHAschSMAdamsJ. The quality of pharmacologic care for adults in the United States. Med Care2006; 44(10): 936–945.
20.
AschSMSlossEMHoganC. Measuring underuse of necessary care among elderly Medicare beneficiaries using inpatient and outpatient claims. JAMA2000; 284(18): 2325–2333.
21.
KuijpersMAvan MarumRJEgbertsAC. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol2008; 65(1): 130–133.
22.
KuzuyaMMasudaYHirakawaY. Underuse of medications for chronic diseases in the oldest of community-dwelling older frail Japanese. J Am Geriatr Soc2006; 54(4): 598–605.
23.
WrightRMSloaneRPieperCF. Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study. Am J Geriatr Pharmacother2009; 7(5): 271–280.
24.
WolffJLStarfieldBAndersonG. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med2002; 162(20): 2269–2276.
25.
BrownAMClelandJG. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J1998; 19(7): 1063–1069.
26.
BraunsteinJBAndersonGFGerstenblithG. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol2003; 42(7): 1226–1233.
27.
CharlsonMEPompeiPAlesKL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis1987; 40(5): 373–383.
28.
CammAJKirchhofPLipGY. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J2010; 31(19): 2369–2429.
29.
FoxKGarciaMAArdissinoD. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J2006; 27(11): 1341–1381.
30.
DicksteinKCohen-SolalAFilippatosG. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J2008; 29(19): 2388–2442.
31.
HoughtonARCowleyAJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?Int J Cardiol1997; 59(1): 7–10.
GageBFCardinalliABOwensDK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke1998; 29(6): 1083–1091.
34.
HanlonJTSchmaderKEKoronkowskiMJ. Adverse drug events in high risk older outpatients. J Am Geriatr Soc1997; 45(8): 945–948.
35.
GurwitzJHFieldTSHarroldLR. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA2003; 289(9): 1107–1116.
36.
MasoudiFARathoreSSWangY. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation2004; 110(6): 724–731.
37.
Robert-EbadiHLe GalGRighiniM. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging2009; 4: 165–177.
38.
TulnerLRVan CampenJPKuperIM. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging2010; 27(1): 39–50.
39.
KimMHKlingmanDLinJ. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy2009; 29(12): 1417–1426.
40.
YeXGrossCRSchommerJ. Initiation of statins after hospitalization for coronary heart disease. J Manag Care Pharm2007; 13(5): 385–396.
41.
RochonPAAndersonGMTuJV. Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario. CMAJ1999; 161(11): 1403–1408.
42.
OstbyeTYarnallKSKrauseKM. Is there time for management of patients with chronic diseases in primary care?Ann Fam Med2005; 3(3): 209–214.
43.
HigashiTWengerNSAdamsJL. Relationship between number of medical conditions and quality of care. N Engl J Med2007; 356(24): 2496–2504.
44.
BaumeisterSEDörrMRadkeD. Predictive modeling of health care costs: do cardiovascular risk markers improve prediction?Eur J Cardiovasc Prev Rehabil2010; 17(3): 355–362.
